Zyversa Therapeutics, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
OQB
ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, is raising up to $14.1 million through equity agreements and warrant exercises while navigating a Nasdaq delisting and significant going concern doubts.
OQB
ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, is registering shares for resale to raise capital following its delisting from Nasdaq and amidst significant financial challenges, including substantial doubt about its ability to continue as a going concern.
OQB
ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, has entered into an equity purchase agreement to raise up to $10 million, while simultaneously facing substantial doubt about its ability to continue as a going concern and ongoing Nasdaq listing compliance challenges.